The Company has previously received an aggregate total of Four Million Dollars ($4,000,000) of the Offering prior to the current Purchase Option exercise. The exercise of the remaining One Million Dollars ($1,000,000) of the Purchase Option completes the issuance of all Shares allowed and thereby closes the Purchase Option of the Offering. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis. “We are pleased to announce the successful completion of the $5 million equity financing through the full exercise of the remaining shares under the Purchase Option.